---
title: "石药集团创新药 SYH2085 获准开展临床试验"
description: "石药集团公布，集团开发的化学 1 类创新药 SYH2085 片获中国国家药品监督管理局批准，可在中国开展临床试验。本次获批的临床适应症为用于治疗成人及 12 岁以上青少年单纯性甲型和乙型流感。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/270403949.md"
published_at: "2025-12-21T12:01:54.000Z"
---

# 石药集团创新药 SYH2085 获准开展临床试验

> 石药集团公布，集团开发的化学 1 类创新药 SYH2085 片获中国国家药品监督管理局批准，可在中国开展临床试验。本次获批的临床适应症为用于治疗成人及 12 岁以上青少年单纯性甲型和乙型流感。

石药集团 (01093.HK) 公布，集团开发的化学 1 类创新药 SYH2085 片获中国国家药品监督管理局批准，可在中国开展临床试验。本次获批的临床适应症为用於治疗成人及 12 岁以上青少年单纯性甲型和乙型流感。

### Related Stocks

- [01093.HK - 石药集团](https://longbridge.com/zh-CN/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical Group Receives FDA Approval for SYH2082 Clinical Trial in the US | CSPC Pharmaceutical Group Ltd. has received FDA approval to conduct clinical trials for SYH2082, a GLP-1/GIP receptor du | [Link](https://longbridge.com/zh-CN/news/276033771.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| 11:08 ETAmericans Wash Hands More During Flu Season but Everyday Habits Still Fall Short, New Survey Finds | A recent survey reveals that 70% of Americans are concerned about contracting the flu, up from 59% three years ago. The  | [Link](https://longbridge.com/zh-CN/news/275633689.md) |
| CSPC Pharma Gets China Nod for Multiple Drug Trials | CSPC Pharma Gets China Nod for Multiple Drug Trials | [Link](https://longbridge.com/zh-CN/news/270994613.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/zh-CN/news/274393834.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
